172 related articles for article (PubMed ID: 37724763)
1. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.
Kasaie P; Pennington J; Gupta A; Dowdy DW; Kendall EA
Clin Infect Dis; 2024 Jan; 78(1):133-143. PubMed ID: 37724763
[TBL] [Abstract][Full Text] [Related]
2. Trials underestimate the impact of preventive treatment for household contacts exposed to multidrug-resistant tuberculosis: a simulation study.
Kasaie P; Pennington J; Gupta A; Dowdy DW; Kendall EA
medRxiv; 2023 Feb; ():. PubMed ID: 36798407
[TBL] [Abstract][Full Text] [Related]
3. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
[TBL] [Abstract][Full Text] [Related]
4. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study.
Suryavanshi N; Murrill M; Gupta A; Hughes M; Hesseling A; Kim S; Naini L; Jones L; Smith B; Gupte N; Dawson R; Mave V; Meshram S; Mendoza-Ticona A; Sanchez J; Kumarasamy N; Comins K; Conradie F; Shenje J; Nerette Fontain S; Garcia-Prats A; Asmelash A; Nedsuwan S; Mohapi L; Lalloo U; Cristina Garcia Ferreira A; Okeyo E; Swindells S; Churchyard G; Shah NS
Clin Infect Dis; 2020 Jan; 70(3):436-445. PubMed ID: 30919881
[TBL] [Abstract][Full Text] [Related]
5. A study of multidrug resistant tuberculosis among symptomatic household contacts of MDR-TB patients.
Shadrach BJ; Kumar S; Deokar K; Singh GV; Hariharan ; Goel R
Indian J Tuberc; 2021 Jan; 68(1):25-31. PubMed ID: 33641847
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.
Kendall EA; Hussain H; Kunkel A; Kubiak RW; Trajman A; Menzies R; Drain PK
BMC Med; 2021 Dec; 19(1):315. PubMed ID: 34903214
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Zhou G; Luo S; He J; Chen N; Zhang Y; Cai S; Guo X; Chen H; Song C
Clin Microbiol Infect; 2024 Feb; 30(2):189-196. PubMed ID: 37741621
[TBL] [Abstract][Full Text] [Related]
8. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
[TBL] [Abstract][Full Text] [Related]
9. Caregiver willingness to give TPT to children living with drug-resistant TB patients.
Rouzier V; Murrill M; Kim S; Naini L; Shenje J; Mitchell E; Raesi M; Lourens M; Mendoza A; Conradie F; Suryavanshi N; Hughes M; Shah S; Churchyard G; Swindells S; Hesseling A; Gupta A
Int J Tuberc Lung Dis; 2022 Oct; 26(10):949-955. PubMed ID: 36163664
[TBL] [Abstract][Full Text] [Related]
10. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
11. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, treatment and transmission of rifampicin-resistant TB in the Netherlands, 2010-2019.
de Vries G; Akkerman O; Boeree M; van Hest R; Kamst M; de Lange W; Magis-Escurra C; Meijer W; van Soolingen D
Int J Tuberc Lung Dis; 2023 Jun; 27(6):471-477. PubMed ID: 37231607
[No Abstract] [Full Text] [Related]
13. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.
Vella V; Racalbuto V; Guerra R; Marra C; Moll A; Mhlanga Z; Maluleke M; Mhlope H; Margot B; Friedland G; Shah NS; Gandhi NR
Int J Tuberc Lung Dis; 2011 Sep; 15(9):1170-5, i. PubMed ID: 21943840
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India.
Singla N; Singla R; Jain G; Habib L; Behera D
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1326-30. PubMed ID: 22283889
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
[TBL] [Abstract][Full Text] [Related]
16. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
17. Active contact tracing beyond the household in multidrug resistant tuberculosis in Vietnam: a cohort study.
Hoang TTT; Nguyen VN; Dinh NS; Thwaites G; Nguyen TA; van Doorn HR; Cobelens F; Wertheim HFL
BMC Public Health; 2019 Feb; 19(1):241. PubMed ID: 30819161
[TBL] [Abstract][Full Text] [Related]
18. Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011-2017: A Retrospective Cohort Study (Korean TB-POST).
Choi H; Mok J; Kang YA; Jeong D; Kang HY; Kim HJ; Kim HS; Jeon D
J Korean Med Sci; 2023 Feb; 38(5):e33. PubMed ID: 36747362
[TBL] [Abstract][Full Text] [Related]
19. Exposed! Management of MDR-TB household contacts in an evidence light era.
Gaskell KM; Allen R; Moore DAJ
Int J Infect Dis; 2019 Mar; 80S():S13-S16. PubMed ID: 30825653
[TBL] [Abstract][Full Text] [Related]
20. Multi-drug resistant and rifampin-resistant tuberculosis in transplant recipients.
Abad CLR; Razonable RR
Transpl Infect Dis; 2023 Aug; 25(4):e14088. PubMed ID: 37335213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
